A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 2,501–2,600 of 3,967
Schreiber, J., Schütte, W., Koerber, W., Seese, B., Koschel, D., Neuland, K., & Grohé, C. (2024) · Pneumologie · doi:10.1055/a-2267-2074 · Cited by 6
The multifaceted role of macrophage mitophagy in SiO2‐induced pulmonary fibrosis: A brief review
Zhou, Y., Li, S., Du, S., Zhao, J., Cai, Y., & Zhang, Z. (2024) · Journal of Applied Toxicology · doi:10.1002/jat.4612 · Cited by 8
Gao, Z.-Y., Xu, M.-Z., Liu, C., Gong, K., Yu, X., Lu, K., Zhu, J., Guan, H., & Zhu, Q. (2024) · Pharmaceuticals · doi:10.3390/ph17050584 · Cited by 5
Samarelli, A. V., Tonelli, R., Raineri, G., Mastrolia, I., Costantini, M., Fabbiani, L., Catani, V., Petrachi, T., Bruzzi, G., Andrisani, D., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12061321 · Cited by 6
Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives
Vancheri, C., Sciacca, E., Muscato, G., Spicuzza, L., Fruciano, M., Gili, E., Sambataro, G., Palmucci, S., & Libra, A. (2024) · Multidisciplinary Respiratory Medicine · doi:10.5826/mrm.2024.982 · Cited by 14
Freeberg, M. A. T., Thatcher, T. H., Camus, S., Huang, L., Atkinson, J. M., Narrow, W. C., Haak, J., Dylag, A. M., Cowart, L. A., Johnson, T. S., et al. (2024) · Physiological Reports · doi:10.14814/phy2.16012 · Cited by 7
Amubieya, O., Todd, J. L., Neely, M. L., Kaner, R. J., Lasky, J. A., Namen, A. M., Heßlinger, C., Palmer, S. M., WEIGT, S. S., & Belperio, J. A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0312044 · Cited by 8
Pan, C., Wei, H., Chen, B., Wu, L., Song, J., Zhang, Q., Wu, X., Liang, G., Chen, W., Wang, Y., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05895-0 · Cited by 7
Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments
Duong‐Quy, S., Hai, C. N., Huynh-Anh, T., & Nguyen‐Nhu, V. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2438322 · Cited by 5
Examining Cough’s Role and Relief Strategies in Interstitial Lung Disease
Lim, C. Y., Khan, S. W., ALSIBAI, T., & Sathiyamoorthy, G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14010291 · Cited by 6
“Pirfenidone is an antifibrotic and anti-inflammatory agent that inhibits the TGF-B and TNF-a pathways; it is used for the treatment of IPD to slow disease progression [53].”
Advances in Selenium and Related Compounds Inhibiting Multi-Organ Fibrosis
Xiao, X., Huang, G., Yu, X., & Tan, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s488226 · Cited by 6
Pathophysiological Insights and Clinical Management Strategies for Interstitial Lung Diseases
Tian, L., Wang, Y., Qi, W., Wang, B., Zhang, X., Gong, M., Zhang, X., & Wang, T. (2025) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2025.004 · Cited by 10
Idiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease
Tourin, O., Swigris, J. J., & Olson, A. L. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_2 · Cited by 5
Self-citationTransbronchial Cryobiopsy in Interstitial Lung Disease: Advantageous Costs to Benefits Ratio
Montero, Á. (2015) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2015.02.033 · Cited by 5
Velez, M. I., & Nambiar, A. M. (2015) · Respirology · doi:10.1111/resp.12487 · Cited by 5
Adegunsoye, A., Levy, M., & Oyenuga, O. A. (2015) · BioMed Research International · doi:10.1155/2015/929170 · Cited by 5
Varone, F., Mastrobattista, A., Franchi, P., Viglietta, L., Poletti, V. E., Tomassetti, S., Dubini, A., Tagliaboschi, L., Calandriello, L., Farchione, A., et al. (2016) · The Clinical Respiratory Journal · doi:10.1111/crj.12515 · Cited by 5
Sakhri, L., Saint‐Raymond, C., Quétant, S., Pison, C. M., Lagrange, E., Roy, R. H., Janssens, J.-P., Maindet, C., Garrouste-Orgeas, M., Lévy-Soussan, M., et al. (2016) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2016.06.005 · Cited by 3
New Treatments for Idiopathic Pulmonary Fibrosis
Meyer, K. C., & Modi, D. (2016) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000166 · Cited by 5
Pirfenidone and mortality in idiopathic pulmonary fibrosis
Spagnolo, P. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30416-7 · Cited by 7
Nerves, Cough, and Idiopathic Pulmonary Fibrosis
Harrison, N. K., & Pynn, M. (2015) · EMJ Respiratory · doi:10.33590/emjrespir/10312904 · Cited by 5
Cleveland, Z. I., Zhou, Y., Akinyi, T. G., Dunn, R. S., Davidson, C. R., Guo, J., Woods, J. C., & Hardie, W. D. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00458.2016 · Cited by 6
Tolerability of treatment with pirfenidone or nintedanib for pulmonary fibrosis in the real world
Ogura, T., & Kitamura, H. (2017) · Respirology · doi:10.1111/resp.13059 · Cited by 5
Pirfenidone for primary Sjögren's syndrome-related fibrotic interstitial pneumonia.
Enomoto, Y., Nakamura, Y., Colby, T. V., et al. (2017) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v34i1.5091 · Cited by 5
Pirfenidone in Idiopathic Pulmonary Fibrosis “RECAP-itulating Safety into the Real World”
Τzouvelekis, Α., Bouros, E., Tzilas, V., & Bouros, D. E. (2017) · Respiration · doi:10.1159/000480299 · Cited by 6
Inchingolo, R., Condoluci, C., Smargiassi, A., Mastrobattista, A., Boccabella, C., Comes, A., Golfi, N., & Richeldi, L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1383382 · Cited by 7
Suda, K., Kamiya, K., Chiang, B., Okada, H., Mato, N., Maekawa, T., Komine, M., Murata, S., & Ohtsuki, M. (2018) · Allergology International · doi:10.1016/j.alit.2018.02.010 · Cited by 5
Cell division cycle 7 kinase is a negative regulator of cell-mediated collagen degradation
Podolsky, M. J., Gupta, D., Ha, A., Ta, R., Khalifeh‐Soltani, A., McKleroy, W., Datta, R., Sheppard, D., & Atabai, K. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00144.2018 · Cited by 5
Wells, A. U. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30385-0 · Cited by 5
Twenty‐five years of Respirology: Advances in idiopathic pulmonary fibrosis
Varone, F., Inoue, Y., & Richeldi, L. (2019) · Respirology · doi:10.1111/resp.13733 · Cited by 7
Sakamoto, S., Shimizu, H., Isshiki, T., Kurosaki, A., & Homma, S. A. (2019) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v36i3.7750 · Cited by 7
Min, H. K., Kim, S., Lee, S., & Kim, H. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.443 · Cited by 5
Imakura, T., Toyoda, Y., Sato, S., et al. (2020) · The Journal of Medical Investigation · doi:10.2152/jmi.67.358 · Cited by 5
Use of Nintedanib and Pirfenidone in Non–Idiopathic Pulmonary Fibrosis Lung Disease
Warrior, K., Chung, P. A., Reid, M., & Bemiss, B. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202012-4356rr · Cited by 5
Chen, C.-Y., Chen, C., Wang, C., Lai, C., Chao, C., & Wei, Y. (2021) · Respiratory Research · doi:10.1186/s12931-021-01839-0 · Cited by 5
Comparison of Palliative Care Models in Idiopathic Pulmonary Fibrosis
Younus, S., Bakal, J. A., Richman–Eisenstat, J., et al. (2021) · Applied Sciences · doi:10.3390/app11199028 · Cited by 5
“Higher proportion of patients in our study were on ambulatory oxygen overall (56%) when compared to around 20% in clinical trials cohorts and other registry studies [29,30].”
ResultRetrospective analysis of skin photosensitivity induced by pirfenidone
Wang, C., He, Y., Sun, W., Wu, C., Li, Z., & Sun, L. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13542 · Cited by 6
Boleto, G., Avouac, J., & Allanore, Y. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211066686 · Cited by 6
Yamakawa, H., Tsukahara, Y., Sato, S., Ohta, H., Kida, G., Nakamura, T., Nishizawa, T., Kawabe, R., Oba, T., Akasaka, K., et al. (2022) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v38i4.11465 · Cited by 5
Mlakar, L., Garrett, S. M., Watanabe, T., Sanderson, M., Nishimoto, T., Heywood, J., Helke, K. L., Pilewski, J. M., Herzog, E. L., & Feghali‐Bostwick, C. A. (2022) · Biomedicines · doi:10.3390/biomedicines10112861 · Cited by 6
“Therefore, END55 was tested in fibrotic human lung cores derived from patients with IPF and SSc who underwent lung transplantation.”
BackgroundInfluentialCocconcelli, E., Bernardinello, N., Giraudo, C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415890 · Cited by 5
“Pirfenidone and nintedanib are approved for treatment of IPF worldwide, based on their ability to slow down functional decline and disease progression with an acceptable safety and tolerability profile [24,25].”
BackgroundImmunosuppression in lung transplantation: a narrative review
Atkinson, B. J., & Sharma, N. (2023) · Current Challenges in Thoracic Surgery · doi:10.21037/ccts-21-42 · Cited by 4
Imaging of pulmonary fibrosis in children: A review, with proposed diagnostic criteria
DeBoer, E. M., Weinman, J. P., Ley‐Zaporozhan, J., Griese, M., Deterding, R. R., Lynch, D. A., Humphries, S. M., & Jacob, J. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.26857 · Cited by 9
(2000) · Time to knit · doi:10.1016/j.ypdi.2015.02.056 · Cited by 5
The Role of Epithelial Cell Quality Control in Health and Disease of the Distal Lung
Beers, M. F., Nureki, S., & Mulugeta, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803809-3.00008-7 · Cited by 7
Mortality in interstitial lung disease: do race and skin colour matter?
Morisset, J., Mageto, Y. N., & Raghu, G. (2018) · European Respiratory Journal · doi:10.1183/13993003.00892-2018 · Cited by 5
Mohning, M. P., Downey, G. P., Cosgrove, G. P., & Redente, E. F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54431-3.00003-2 · Cited by 122
Chen, L., Halai, V., Leandru, A., & Wallis, A. (2019) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000000915 · Cited by 6
Evaluation of antifibrotic effect of pirfenidone on human nasal mucosal fibroblast cell culture
Atkova, E. L., Krakhovetskiy, N. N., Ярцев, В. Д., Суббот, А. М., Gabashvili, A. N., Rein, D. A., & Nesterova, T. V. (2018) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn942 · Cited by 5
Majewski, S., Lewandowska, K. B., Martusewicz-Boros, M. M., & Piotrowski, W. J. (2020) · Advances in respiratory medicine · doi:10.5603/arm.2019.0060 · Cited by 6
The world is not enough – the value of increasing registry data in idiopathic pulmonary fibrosis
Moor, C. C., Kreuter, M., Luppi, F., & Wuyts, W. A. (2020) · Respiratory Research · doi:10.1186/s12931-020-01377-1 · Cited by 7
New guideline on treatment of idiopathic pulmonary fibrosis
Spagnolo, P., Bonella, F., & Maher, T. M. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00322-7 · Cited by 5
Die idiopathische Lungenfibrose
Prasse, A. (2015) · Pneumologie · doi:10.1055/s-0034-1393036 · Cited by 5
MicroRNAs in Idiopathic Pulmonary Fibrosis
Pandit, K. V., & Kaminski, N. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800553-8.00007-x · Cited by 5
Nintedanib for idiopathic pulmonary fibrosis in the J apanese population
Jo, H. E., & Corte, T. J. (2017) · Respirology · doi:10.1111/resp.13033 · Cited by 5
Familial pulmonary fibrosis: a world without frontiers
Borie, R., & Crestani, B. (2019) · Jornal Brasileiro de Pneumologia · doi:10.1590/1806-3713/e20190303 · Cited by 6
Pulmonary Hypertension due to Fibrotic Lung Disease: Hidden Value in a Neutral Trial
Nathan, S. D., & Carbone, R. G. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201406-1094ed · Cited by 5
Self-citationMaldonado, F., & Kropski, J. A. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.02.331 · Cited by 5
Solomon, J. J., Danoff, S. K., Woodhead, F., et al. (2022) · medRxiv · doi:10.1101/2022.04.01.22273270 · Cited by 5
Self-citationMaher, T. M., Hamblin, M. J., Choi, W.-I., Case, A. H., Tomos, I. P., Tzouvelekis, A. E., Shore, J. E., Bergna, M. A., Golod, D., Elenko, E., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag155 · Cited by 4
Matics, Z., Bardóczi, A. B., Galkó, C., Szabó, B., Gede, N., Molnár, Z., Duray, G. Z., Turan, C., Hegyi, P., Horváth, G., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102966 · Cited by 4
Bava, E. P., Jain, T., Al‐Obaidi, M., et al. (2025) · Pancreatology · doi:10.1016/j.pan.2025.01.004 · Cited by 4
Liu, X., Lu, F., Yang, H., Liao, G., Zhao, L., Zou, D., He, T., Hu, Y., Wang, L., Xia, J., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14896-1 · Cited by 7
Hasan, M. R., Chae, Y., Lee, S. Y., & Kang, Y. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-18370-7 · Cited by 10
Chitosan Nanoparticles for Pulmonary Delivery of Curcumin/Nintedanib to Treat Pulmonary Fibrosis
Jin, M., Liu, J., Shao, M., He, S., He, Y., Yang, Q., & Yang, G. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s522929 · Cited by 5
Kim, B., Han, K., Park, J., Kim, B., Han, D., Chung, S. J., Kang, H. K., Kim, S., Park, M. S., Sohn, J. W., et al. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251406024 · Cited by 4
Ma, X., Zhu, L., Xiao, H., He, Y., & Dai, H. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.11.008 · Cited by 6
Su, H., Fan, X., Nie, C., Tang, X., Hu, J., Xu, K., Zhang, L., & Ma, D. (2026) · Biomolecules · doi:10.3390/biom16010072 · Cited by 6
“Pirfenidone, another important anti-fibrotic drug, has been shown in multiple clinical studies to inhibit TGF-β production and ECM deposition, effectively delaying fibrosis progression [99–102].”
Corneal Neovascularization: Pathogenesis, Current Insights and Future Strategies
Muller, E., Feinberg, L. J., Woronkowicz, M., & Roberts, H. W. (2026) · Biology · doi:10.3390/biology15020136 · Cited by 9
Wuyts, W. A., LANCASTER, L. H., Maher, T. M., Ryerson, C. J., Kreuter, M., Corte, T. J., Valenzuela, C., Barnes, C. N., Lefebvre, E. A., Cosgrove, G. P., et al. (2026) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-002937 · Cited by 8
Self-citationImmunometabolism in Cardiac Remodeling: Mechanisms and Therapeutic Perspectives
Nazaruk, J., Bilnik, B., Niewiadomski, M., Pawlak, W., & Gajewski, P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093906 · Cited by 7
“For example, pirfenidone and nintedanib have been shown to inhibit fibroblast activation and extracellular matrix deposition in both experimental studies and clinical trials [102,103].”
Chronic Respiratory Disease: COPD, IPF
Incalzi, R. A., & Fimognari, F. L. (2023) · Practical issues in geriatrics · doi:10.1007/978-3-031-28061-0_22 · Cited by 4
Disease progression in idiopathic pulmonary fibrosis under anti-fibrotic treatment.
Çilli, A., & Üzer, F. (2023) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v40i3.14048 · Cited by 12
Gregor, J., Adir, Y., Šterclová, M., Moğulkoç, N., Kramer, M. R., Doubková, M., Plačková, M., Müller, V., Studnicka, M., Žůrková, M., et al. (2023) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2023.12.002 · Cited by 5
Biology of neurofibrosis with focus on multiple sclerosis
Lozinski, B. M., Ghorbani, S., & Yong, V. W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1370107 · Cited by 9
Modified blood cell GAP model as a prognostic biomarker in idiopathic pulmonary fibrosis
Kreuter, M., Lee, J. S., Tzouvelekis, A., Oldham, J. M., Molyneaux, P. L., Weycker, D. A., Atwood, M., Samara, K. D., Kirchgässler, K.-U., & Maher, T. M. (2024) · ERJ Open Research · doi:10.1183/23120541.00666-2023 · Cited by 5
Pugashetti, J. V., Kim, J. S., Combs, M. P., Ma, S., Adegunsoye, A., Linderholm, A., Strek, M. E., Chen, C., Dilling, D. F., Whelan, T. P. M., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.03.018 · Cited by 4
Clinical utility, reproducibility, and radiologist acceptance of ILD-RADS
Elshetry, A. S. F., El-fawakry, R. M., Zaiton, F., et al. (2024) · European Journal of Radiology · doi:10.1016/j.ejrad.2024.111473 · Cited by 4
Current challenges in the diagnosis and management of idiopathic pulmonary fibrosis in Japan
Bando, M., Chiba, H., Miyazaki, Y., & Suda, T. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.06.006 · Cited by 7
Quality of life in idiopathic pulmonary fibrosis in Latin American countries
Aguilar‐Duran, H., Fernández, M., González-García, M., Rincón-Álvarez, E., Alberti, M. L., Caro, F. M., Tavera, E., Vásquez, E., Cortez, N., Salinas, M., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03506-2 · Cited by 6
Epidemiology of idiopathic pulmonary fibrosis in central and Western Pennsylvania
Linkov, F. Y., Chang, Y., Ramanan, H., Morgan, R. S., McTigue, K. M., Dimmock, A. E. F., Bascom, R., & Kass, D. J. (2025) · Respiratory Research · doi:10.1186/s12931-025-03164-2 · Cited by 4
Development of a Polidocanol-based Human In Vitro Model to Explore Airway Epithelial Repair
Chakraborty, A., Zöller, M., Sardogan, A., Klotz, M., Mastalerz, M., Marchi, H., Meixner, R., Hatz, R. A., Behr, J., Hilgendorff, A., et al. (2025) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0117oc · Cited by 8
Wang, R., Yang, F., Liu, Y., Peng, M., Yu, L., Hou, Q., Liu, Y., & Cheng, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1506518 · Cited by 5
Graham, C. S., Bisson, B., Shore, J. E., Pardy, E., Salisbury, F., LANCASTER, L. H., & Kulkarni, T. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03689-8 · Cited by 5
Self-citationYang, Z. H., Yao, Y., Chen, X., Madigan, V. J., Pu, S., Fan, X., Pu, J., & Bei, F. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102144 · Cited by 7
Du, Y., Zhu, C., Wang, R., Chen, S., Li, C., Ouyang, D., Liu, L., & Chen, Y. (2025) · Advanced Science · doi:10.1002/advs.202505357 · Cited by 4
Ito, K., Kato, S., Yasuda, N., Sawamura, S., Fukui, K., Iwasawa, T., Ogura, T., & Utsunomiya, D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155329 · Cited by 4
“Pirfenidone and nintedanib, approved based on large-scale randomized trials such as ASCEND and INPULSIS, have demonstrated efficacy in slowing disease progression in idiopathic pulmonary fibrosis (IPF) and progressive fibrosing ILDs [22,23].”
Zhao, L., Liu, H., Yao, X., Ma, X., Liu, B., Li, B., Tong, H. H. Y., & Zhang, Q. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01521 · Cited by 4
P, Á. U. (2015) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2015.06.006 · Cited by 36
Jo, H. E., Corte, T. J., Wort, S. J., Eves, N. D., Piper, A. J., & Wainwright, C. E. (2016) · Respirology · doi:10.1111/resp.12749 · Cited by 5
Кузубова, Н. А., Titova, O. N., & Sklyarova, D. B. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-17-99-106 · Cited by 4
Management and support of patients with fibrosing interstitial lung diseases
Barbera, T., Davila, L., & Patel, N. M. (2021) · The Nurse Practitioner · doi:10.1097/01.npr.0000743332.64602.aa · Cited by 4
Wang, R. T., Xu, J., Yan, R., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.998245 · Cited by 4
“Currently, the drugs nintedanib (NDNB) and pirfenidone (PFD) have been used in the clinical treatment of IPF (King et al., 2014; Richeldi et al., 2014).”
BackgroundThe road to hell is paved with good intentions: a look back at the PANTHER-IPF trial
Kam, M. L. W., Caliez, J., Nunès, H., & Gille, T. (2022) · Breathe · doi:10.1183/20734735.0074-2022 · Cited by 6
Matsumoto, K., Suzuki, K., Yasuoka, H., Hirahashi, J., Yoshida, H., Magi, M., Noguchi‐Sasaki, M., Kaneko, Y., & Takeuchi, T. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103271 · Cited by 5
Lee, C. (2023) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14626 · Cited by 6
Aoki, A., Hara, Y., Fujii, H., Murohashi, K., Nagasawa, R., Tagami, Y., Enomoto, T., Matsumoto, Y., Masuda, M., Watanabe, K., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291489 · Cited by 5
Chang, C., Wei, Y.-F., Chen, C., Lai, Y.-C., Hu, P., Hung, J.-C., Chu, C., Chuang, H.-T., & Chang, S. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1242260 · Cited by 4
Cao, Z., Ramadan, A. M., Tai, A., Zetterberg, F. R., & Panjwani, N. (2023) · American Journal Of Pathology · doi:10.1016/j.ajpath.2023.11.018 · Cited by 6
Circulating biomarker analyses in a longitudinal cohort of patients with IPF
Ebert, C., Walsh, A. M., Sereda, L., Wilson, C. L., Schafer, P. H., Fischer, A., Zhao, L., Ramírez‐Valle, F., Gordon, D., & Schnapp, L. M. (2024) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00222.2023 · Cited by 5
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.